ADXN on Nasdaq
Addex Therapeutics Ltd.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue from contract with customer | 30.0K CHF | 404.1K CHF | 1.6M CHF |
| Other income | 142.9K CHF | 5.9K CHF | 4.2K CHF |
| Research and development | -671.7K CHF | -854.3K CHF | -1.2M CHF |
| General and administration | -2.3M CHF | -2.3M CHF | -2.7M CHF |
| Total operating costs | -3.0M CHF | -3.2M CHF | -3.9M CHF |
| Operating loss | -2.8M CHF | -2.8M CHF | -2.2M CHF |
| Finance income | 26.6K CHF | 64.0K CHF | |
| Finance expense | -15.5K CHF | -3.5K CHF | -321.1K CHF |
| Finance result | -15.5K CHF | 23.0K CHF | -257.2K CHF |
| Share of net loss of investments accounted for using the equity method | -4.0M CHF | -2.2M CHF | |
| Net loss before tax from continuing operations | -6.8M CHF | -4.9M CHF | -2.5M CHF |
| Income tax expense | 0 CHF | 0 CHF | 0 CHF |
| Net loss from continuing operations | -6.8M CHF | -4.9M CHF | -2.5M CHF |
| Net profit / (loss) from discontinued operations (attributable to equity holders of the Group) | 114.3K CHF | 12.0M CHF | -8.1M CHF |
| Net profit / (loss) for the period | -6.7M CHF | 7.1M CHF | -10.6M CHF |
| Basic profit / (loss) per share for profit/(loss) attributable to the ordinary equity holders of the Company | -0.06 CHF | 0.07 CHF | -0.14 CHF |
| From continuing operations | -0.06 CHF | -0.05 CHF | -0.03 CHF |
| From discontinued operations | 0.12 CHF | -0.11 CHF | |
| Diluted profit / (loss) per share for profit/ (loss) attributable to the ordinary equity holders of the Company | -0.06 CHF | 0.07 CHF | -0.14 CHF |
| From continuing operations | -0.06 CHF | -0.05 CHF | -0.03 CHF |
| From discontinued operations | 0.12 CHF | -0.11 CHF |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | 1.6M CHF | 3.3M CHF | 3.9M CHF |
| Other financial assets | 5.1K CHF | 6.5K CHF | |
| Trade and other receivables | 20.1K CHF | 15.5K CHF | |
| Prepayments | 16.3K CHF | 169.6K CHF | |
| Other short-term assets | 8.0K CHF | ||
| Total current assets | 1.7M CHF | 3.5M CHF | |
| Right-of-use assets | 33.5K CHF | 41.6K CHF | 330.3K CHF |
| Equipment | 707 CHF | 1.1K CHF | 22.6K CHF |
| Non-current financial assets | 7.1K CHF | 7.1K CHF | |
| Investment accounted for using the equity method | 3.8M CHF | 7.1M CHF | |
| Financial assets at fair value through other comprehensive income | 286.0K CHF | ||
| Derivative financial instrument | 509.1K CHF | ||
| Total non-current assets | 4.7M CHF | 7.1M CHF | |
| Total assets | 6.4M CHF | 10.7M CHF | |
| Current lease liabilities | 7.7K CHF | 7.3K CHF | |
| Payables and accruals | 1.2M CHF | 794.8K CHF | |
| Total current liabilities | 1.2M CHF | 802.1K CHF | |
| Non-current lease liabilities | 27.0K CHF | 34.7K CHF | |
| Retirement benefits obligations | 371.6K CHF | 164.3K CHF | |
| Total non-current liabilities | 398.6K CHF | 198.9K CHF | |
| Share capital | 2.2M CHF | 1.8M CHF | |
| Share premium | 267.3M CHF | 266.4M CHF | |
| Other equity | 64.6M CHF | 64.6M CHF | |
| Treasury shares reserve | -1.0M CHF | -869.7K CHF | |
| Other reserves | 31.8M CHF | 31.1M CHF | |
| Accumulated deficit | -360.1M CHF | -353.4M CHF | |
| Total equity | 4.8M CHF | 9.7M CHF | 1.1M CHF |
| Total liabilities and equity | 6.4M CHF | 10.7M CHF |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net profit / (loss) for the period | -6.7M CHF | 7.1M CHF | -10.6M CHF |
| Net gain on Neurosterix Transaction | -114.3K CHF | -13.9M CHF | |
| Fair value of services received at zero cost recorded as income | -141.0K CHF | ||
| Fair value of services received at zero cost recorded as other operating costs | 141.0K CHF | ||
| Value of share-based services | 70.8K CHF | 503.0K CHF | 1.8M CHF |
| Post-employment benefits | -7.2K CHF | -95.2K CHF | -62.6K CHF |
| Share of the net loss of associates | 4.0M CHF | 2.2M CHF | |
| Depreciation | 8.5K CHF | 260.1K CHF | 306.0K CHF |
| Net gain related to lease modification | -2.8K CHF | -318 CHF | |
| Finance cost / (income) net | 37.6K CHF | -99.6K CHF | 312.6K CHF |
| Decrease / (increase) in other financial assets | 1.4K CHF | -5.6K CHF | 2.3K CHF |
| Decrease / (increase) in trade and other receivables | -4.6K CHF | 93.1K CHF | 306.5K CHF |
| Decrease in contract asset | 40.9K CHF | 140.5K CHF | |
| Decrease / (increase) in prepayments | 153.4K CHF | -164.3K CHF | 53.4K CHF |
| Decrease / (increase) in other current assets | 8.0K CHF | -8.0K CHF | |
| Increase / (decrease) in payables and accruals | 391.2K CHF | -1.1M CHF | -613.2K CHF |
| Decrease in deferred income | -38.4K CHF | 324.2K CHF | |
| Net cash used in operating activities | -2.2M CHF | -5.4M CHF | -8.0M CHF |
| Consideration from Neurosterix Transaction | 114.3K CHF | 5.1M CHF | |
| Legal fees paid for Neurosterix Transaction | -473.3K CHF | ||
| Investment in Stalicla SA - preferred shares | -286.0K CHF | ||
| Investment in Stalicla SA - derivative financial instruments | -509.1K CHF | ||
| Purchase of property, plant and equipment | 0 CHF | -1.3K CHF | -6.8K CHF |
| Net cash from/(used in) investing activities | -680.7K CHF | 4.6M CHF | -6.8K CHF |
| Sale of treasury shares | 1.2M CHF | 240.9K CHF | 2.4M CHF |
| Cost paid on sale of treasury shares | -28.9K CHF | -25.8K CHF | -48.1K CHF |
| Cost of treasury share issuance | -6.3K CHF | -53.6K CHF | |
| Proceeds from the exercise of pre-funded warrants | 3.4M CHF | ||
| Costs paid on exercise of pre-funded warrants | -36.5K CHF | -163.1K CHF | |
| Principal element of lease payment | -7.3K CHF | -73.7K CHF | -281.8K CHF |
| Interest received | 9.2K CHF | 64.0K CHF | |
| Interest paid | -2.4K CHF | -9.2K CHF | -21.6K CHF |
| Net cash from financing activities | 1.2M CHF | 104.9K CHF | 5.3M CHF |
| Decrease in cash and cash equivalents | -1.7M CHF | -623.4K CHF | -2.7M CHF |
| Exchange difference on cash and cash equivalents | -35.2K CHF | 99.7K CHF | -356.9K CHF |
| Share of net loss of associates | -4.0M CHF | -2.2M CHF |
Recent filings
- Oct 8, 20266-K
- Oct 2, 20266-K
- Sep 28, 20266-K
- Sep 25, 20266-K
- Sep 4, 2026SCHEDULE 13D/A
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Sep 4, 20264 OWNERSHIP DOCUMENT
- Aug 27, 2026SCHEDULE 13D/A
- Aug 26, 20266-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9